Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of aggressive lymphomas with a generally poor prognosis.
• Understanding the comparative clinical behavior and outcomes of PTCLs versus diffuse large B-cell lymphoma (DLBCL) is crucial for treatment strategies.

Purpose of the Study:

• To compare the clinical characteristics and treatment outcomes of patients with PTCLs against those with DLBCL.
• To identify factors contributing to the differential prognosis between PTCLs and DLBCL.

Main Methods:

• Retrospective analysis comparing 59 PTCL patients (including angioimmunoblastic T-cell lymphoma and unspecified PTCL) with 193 DLBCL patients treated before rituximab.
• Evaluation of clinical features, response rates (complete response/unconfirmed complete response), and survival metrics (overall survival, progression-free survival, disease-free survival).

Main Results:

• PTCL patients more frequently presented with elevated LDH, poor performance status, advanced stage, higher International Prognostic Index scores, and B symptoms compared to DLBCL patients.
• DLBCL patients achieved higher rates of complete or unconfirmed complete response (72% vs. 56%) and demonstrated significantly better 5-year survival rates across all metrics (OS, PFS, DFS) compared to PTCL patients.
• Multivariate analysis identified several risk factors impacting PTCL outcomes, but immunophenotype was not a significant predictor for response or survival.

Conclusions:

• The inferior response and survival observed in PTCL patients are attributable to multiple initial clinical risk factors rather than the T-cell phenotype itself.
• These findings underscore the aggressive nature of PTCLs and the importance of considering baseline prognostic indicators in patient management.